
    
      This is a multi-institution phase II study of ATRA in combination with fixed dose
      Daratumumab, Pomalidomide and Dex for a total of 33 patients in patients with relapsed
      multiple myeloma who have progressed on the combination of Dara + Len + Dex. There will also
      be an exploratory cohort with an additional 10 patients who have progressed on the
      combination of Dara + Pom + Dex.
    
  